Small UK biotech touts long-term data for hemophilia B gene therapy as it attempts a comeback

Aayushi Pratap

News Reporter

As it continues pushing its hemophilia B gene therapy toward the FDA, small biotech Freeline Therapeutics is hoping new long-term data will boost its case …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Small UK biotech touts long-term data for hemophilia B gene therapy as it attempts a comeback

Aayushi Pratap

News Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Will CRISPR matter?

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Small UK biotech touts long-term da­ta for he­mo­phil­ia B gene ther­a­py as it at­tempts a come­back

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Small UK biotech touts long-term data for hemophilia B gene therapy as it attempts a comeback